XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer.

Abstract

BACKGROUND:

Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (mCRC). In this non-randomized pilot study, we investigated the efficacy and safety of sequentially administered XELOX and XELIRI regimens or the reverse sequence in patients with advanced colorectal cancer.

PATIENTS AND METHODS:

Entry criteria were histologically confirmed mCRC, ECOG performance status (PS) < or =2 and adequate bone marrow, renal and hepatic function. All patients consecutively received XELOX followed by XELIRI at disease progression or vice versa.

RESULTS:

In multivariate analysis, independent prognostic factors with worse overall survival were: lower PS (p = 0.0001), multiple metastatic sites (p = 0.016) and high tumor grade. Higher serum levels of alkaline phosphatase and worse ECOG PS were associated with a shorter progression-free survival. Grade 3/4 mucositis, nausea/vomiting, grade 3/4 alopecia and grade 3 diarrhea were more frequent with XELIRI, whereas major toxicity events with XELOX were grade 3 neutropenia, thrombocytopenia and grade 2/3 neurotoxicity.

CONCLUSION:

Capecitabine appears to be an acceptable alternative to continuous-infusion fluorouracil (FU)/leucovorin (LV) in combination therapy and offers an effective, but more convenient alternative to continuous infusion FU/LV in the first-line treatment of patients with mCRC.

• Authors: B Sakar, M Gumus, M Basaran, A Argon, Z Ustuner, M A Ustaoglu, S Saglam, N Guney, A N Tenekeci, N F Aykan
• Journal: Oncology (Oncology) Vol. 73 Issue 5-6 Pg. 298-304 ( 2007) ISSN: 1423-0232 [Electronic] Switzerland
• PMID: 18477855 (Publication Type: Journal Article)
• Copyright: 2008 S. Karger AG, Basel.

Chemical References

• Oxaloacetates
• Deoxycytidine
• Capecitabine
• Irinotecan
• L-Lactate Dehydrogenase
• Fluorouracil
• Camptothecin

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Camptothecin (analogs & derivatives, therapeutic use)
• Capecitabine
• Colorectal Neoplasms (drug therapy, pathology)
• Deoxycytidine (adverse effects, analogs & derivatives, therapeutic use)
• Drug Administration Schedule
• Female
• Fluorouracil (adverse effects, analogs & derivatives, therapeutic use)
• Humans
• Irinotecan
• L-Lactate Dehydrogenase (blood)
• Male
• Middle Aged
• Neoplasm Metastasis
• Neoplasm Staging
• Oxaloacetates
• Pilot Projects
• Randomized Controlled Trials as Topic